Good perspective, thanks.[...]

Great feedback, thanks![...]

Hope it works out for you![...]

Haven't seen any new ads from them recently, but they've been selling an "AI Disruption Playbook" for years n[...]

What do you like about KOPN? See some growth emerging from their defense business, perhaps?Altucher flogged that one like crazy with some very misleading promises that it would be involved with the Apple VisionPro. Don't know if he has given up on that [...]

Rough start for DV -- mild miss on this first earnings report since I bought, and a more significant reduction in the forecasted revenue for 2024.Not cataclysmic, no sign the business is fundamentally broken, but a rough beginning for this one in the[...]

Thanks Stacy![...]

He said they were doing some work on a potential acquisition in Canada. The big private ones are mostly in ag or energy to one degree or another, and he doesn't like bidding wars for public companies... but you never know.[...]

I think that was the pitch for selling puts and covered calls, no? Eifrig has been doing that for a decade or so.[...]

No promises, but a little birdie tells me that Stansberry in the past has recommended:CME LNSTY CBOE ICE BOLSY[...]

Care to elaborate?[...]

That teaser ad is getting pretty long in the tooth now, they haven't updated it since February of 2023... the primary stock they're pitching is Permian Basin Royalty Trust (PBT), which I have a lot of concerns about (primarily their reliance on net profits[...]

Thanks for the perspective... Mission Technologies is a tiny part of the business right now, though it is growing much faster than the shipyards.[...]

Berkshire quarter out -- crazy cash balance approaching $190 billion now.And a somewhat surprising sale of more than 10% of the Apple stake in the quarter... probably responsible, given how massive that position is now, but still a little surprising.[...]

As an actual business, it will be at least several years before we can really guess at how much money they could make as drugs are developed using their technology and make it Through clinical trials.As a biotech or AI story stock, though, anything[...]

Thanks... that's a tough business, personalized immunotherapy that has to be manufactured individually for each patient. Maybe part of the challenge is the history of companies who failed in their attempts at building similar businesses over the past deca[...]

I don't use those particular funds, but I outsource most of my biotech/pharma stock picking to funds as well... can't argue with that. It's important to be aware of the areas where you don't have the background or deep industry knowledge (or interest, eve[...]

Which ones do you like?I write about mostly what people ask about, and what newsletters tease in their promos... sometimes they're more sensible long term ideas, but certainly lots of speculations out there, too.I guess it's easier to get the bloo[...]

For this article? Because it doesn't match the clues at all.In general? Mostly just because POET has been a "story stock" for a decade but hasn't ever built into a real business, and I have no idea when or if they ever will. They have consistently [...]

The spending is so wild in this space that the giant cash-rich folks seem most likely to end up the leaders, but we'll see. SOUN has issued new common (and/or preferred) equity for six quarters in a row, total of about $120 million since mid-2022.[...]